Robotic Nipple Sparing Mastectomy (NSM) Study

Robotic Nipple Sparing Mastectomy (NSM) Study

Brief description of study

The goal of this prospective study is to evaluate the safety and effectiveness of the da Vinci Xi Surgical System, instruments, and accessories in Nipple Sparing Mastectomy, otherwise known as NSM procedures.

Detailed description of study

The primary effectiveness endpoint will evaluate the ability of the da Vinci Xi to complete the NSM procedure without converting to an open approach and the ability to preserve the NAC during the 42-day follow-up period. The primary safety endpoint will evaluate the incidence of intraoperative NSM procedure and device-related adverse events and all post-operative adverse events that occur through the 42-day follow-up period as compared to the published rates reported for open NSM procedures.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Mastectomy,Nipple Sparing Mastectomy (NSM),Prophylactic/Preventative NSM,BRCA 1/2 positive,genetic risk for breast cancer,high risk for breast cancer
  • Age: Between 18 Years - 80 Years
  • Gender: Female

Patients that meet the following criteria will be eligible to participate in the study: 
1. A candidate for unilateral or bilateral nipple sparing mastectomy procedure with immediate reconstruction. 
2. An increased risk for breast cancer and is seeking a prophylactic NSM surgery. 
3. No presence of occult cancer as confirmed by physical exam and by preoperative imaging per institution guidelines. Known carriers of pathogenic BRCA1/2 mutations should have a negative breast MRI.
4. A BMI of less than or equal to 29. 
5. Breast ptosis is less than or equal to Grade 2.
6. Breast cup size is less than or equal to a C cup.
7. At a low to moderate risk for anesthesia.
8. Is willing and able to provide written informed consent. 
9. Is willing and able to comply with the study protocol requirements including follow up examinations up to 5 years (+/- 90 days) post operatively. 

Updated on 09 Mar 2024. Study ID: 834811
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center